Analyst Ratings For Accuray Incorporated (NASDAQ:ARAY)
Today, Citigroup lowered its price target on Accuray Incorporated (NASDAQ:ARAY) to $3.50 per share.
There are 3 Buy Ratings, 2 Sell Ratings, 2 Hold Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Accuray Incorporated (NASDAQ:ARAY) is Hold with a consensus target price of $6.75 per share, a potential 80.00% upside.
Some recent analyst ratings include
- 12/13/2017-Accuray Incorporated (NASDAQ:ARAY) gets downgraded to Underweight by JPMorgan Chase & Co. with a price target of $6.00
- 11/30/2017-Accuray Incorporated (NASDAQ:ARAY) has coverage initiated with a Buy ➝ Buy rating and $10.00 price target
- 10/27/2017-Accuray Incorporated (NASDAQ:ARAY) had its Buy rating reiterated by Cowen with a $9.00 price target
- 8/24/2017-Accuray Incorporated (NASDAQ:ARAY) had its Hold rating reiterated by BTIG Research
Recent Insider Trading Activity For Accuray Incorporated (NASDAQ:ARAY)
Accuray Incorporated (NASDAQ:ARAY) has insider ownership of 3.90% and institutional ownership of 85.17%.
- On 7/3/2018 Alaleh Nouri, SVP, sold 8,559 with an average share price of $4.08 per share and the total transaction amounting to $34,920.72.
- On 7/3/2018 Joshua Levine, CEO, sold 34,235 with an average share price of $4.08 per share and the total transaction amounting to $139,678.80.
- On 7/3/2018 Kevin Waters, CFO, sold 14,265 with an average share price of $4.08 per share and the total transaction amounting to $58,201.20.
- On 4/3/2018 Alaleh Nouri, SVP, sold 2,585 with an average share price of $4.65 per share and the total transaction amounting to $12,020.25.
- On 4/3/2018 Joshua Levine, CEO, sold 8,675 with an average share price of $4.65 per share and the total transaction amounting to $40,338.75.
- On 4/3/2018 Kevin Waters, CFO, sold 2,997 with an average share price of $4.65 per share and the total transaction amounting to $13,936.05.
- On 12/1/2017 Alaleh Nouri, SVP, sold 2,166 with an average share price of $4.86 per share and the total transaction amounting to $10,526.76.
About Accuray Incorporated (NASDAQ:ARAY)
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Recent Trading Activity for Accuray Incorporated (NASDAQ:ARAY)
Shares of Accuray Incorporated closed the previous trading session at 3.75 up +0.22 6.38% with 3.85 shares trading hands.